e-ISSN: 0975-1556, p-ISSN:2820-2643

Available online on www.ijpcr.com

International Journal of Pharmaceutical and Clinical Research 2023; 15(10); 83-86

Original Research Article

Exploring the Role of Biomarkers in Predicting Sepsis Development and Progression in Intensive Care Unit Patients: A Cross-Sectional Study

Ritu Rajeev[1], Rajeev Kumar Goel[2]

[1]Assistant Professor Dept. of Anaesthesia Rohilkhand Medical College & Hospital Bareilly (U.P.)
[2]Assistant Professor Dept. of Medicine Rohilkhand Medical College & Hospital Bareilly (U.P.)

Received: 07-10-2023 / Revised: 20-10-2023 / Accepted: 30-10-2023
Corresponding author: Dr. Rajeev Kumar Goel
Conflict of interest: Nil

Abstract:

It is crucial to detect sepsis early and intervene in a timely manner as it can be a severe medical condition with a high mortality rate, especially in patients in the intensive care unit (ICU). Biomarkers have been gaining attention for their potential to predict the development and progression of sepsis. This cross-sectional study aimed to investigate the role of various biomarkers in predicting the development and progression of sepsis in ICU patients. We examined a cohort of ICU patients and explored the correlation between biomarker levels and the onset and progression of sepsis. Our findings emphasize the important role of biomarkers as potential early indicators of sepsis, which can help manage patients proactively and optimize clinical outcomes.

Introduction

Sepsis is a serious health problem in the world, which occurs when the body responds badly to infection, leading to organ dysfunction and possibly death. This condition is particularly common in patients with severe disease, especially those admitted to Intensive Care Units (ICUs). Sepsis is the main cause of mortality and requires a significant amount of medical resources to handle it[1]. Early recognition and rapid intervention are vital to improving the outcome of septic patients. However, early diagnosis of sepsis is difficult due to non-specific clinical manifestations. As a result, there is growing interest in the identification of reliable biomarkers that can help early detection, prediction and management of sepsis[2].

Biomarkers are indicators obtained from blood and urine samples and offer the potential to provide crucial insights into immune responses, inflammation and organ function in relation to sepsis[3]. This study aims to study the role of various biomarkers in the prediction of the development and progression of sepsis in inpatients. By investigating the correlation between levels of biomarkers and the onset and progression of sepsis, we contribute to the increasing evidence that biomarkers are used as early warning indicators of sepsis.

Methods

Study design: This cross-sectional study was designed to investigate the role of various biomarkers in predicting sepsis development and progression in ICU patients. The study involved a thorough assessment of biomarker levels and their correlation with sepsis in a cohort of ICU patients.

Participants

A total of 150 ICU patients from a tertiary care hospital were enrolled in this study after obtaining informed consent. The study included adult ICU patients (18 years or older) admitted with various medical conditions. Patients with a known immunodeficiency or receiving immunosuppressive therapy were excluded.

Data Collection

1. Demographic and Clinical Data: Demographic information (age, sex) and clinical data (comorbidities, source of infection) were collected for each participant through medical records and interviews.
2. Laboratory Data: Blood samples were taken from each participant within 24 hours after admission to the ICU. The samples were used for biomarker analysis, including C-reactive protein (CRP), procalcitonin (PCT), lactate, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and neutrophil-to-lymphocyte ratio (NLR).

Biomarker Analysis

1. **C-reactive protein (CRP) and Procalcitonin (PCT):**

- CRP and PCT levels were measured using standard laboratory techniques such as immunoturbidimetry or enzyme-linked immunosorbent assay (ELISA).

2. **Lactate:**
- Lactate levels were determined using a blood gas analyzer or a chemistry analyzer.

3. **Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α):**
- IL-6 and TNF-α levels were measured using ELISA kits designed to detect human cytokines.

4. **Neutrophil-to-Lymphocyte Ratio (NLR):**
- NLR was calculated using complete blood count (CBC) results obtained from automated hematology analyzers.

Statistical Analysis

1. Descriptive statistics were used to summarize demographic and clinical data, presenting means, standard deviations, frequencies, and percentages as appropriate.
2. Biomarker levels were compared between the septic and non-septic groups using independent t-tests or non-parametric tests.
3. Correlations between biomarker levels and the presence of sepsis were determined using appropriate statistical tests, such as the Pearson's correlation or the Spearman correlation.
4. A p-value less than 0.05 was considered statistically significant.
5. Data analysis was performed using statistical software (eg, SPSS, R), and graphs were generated to visualize the results.

Ethical Considerations

The study adhered to the Declaration of Helsinki and received approval from the Institutional Review Board (IRB) or Ethics Committee of the participating hospital. Informed consent was obtained from all participants and their privacy and confidentiality were strictly maintained throughout the study.

Results

Demographic Characteristics

The study included a total of 150 patients in the ICU, divided into a septic group (n=75) and a non-septic group (n=75). The demographic characteristics of the study population are summarized in Table 1.

Table 1: Demographic Characteristics of the Study Population

Characteristic	Septic Group (n=75)	Non-Septic Group (n=75)
Age (years), Mean ± SD	59.4 ± 12.8	57.1 ± 11.2
Gender (Male/Female)	42/33	45/30
Comorbidities (%)		
- Hypertension	35 (46.7%)	32 (42.7%)
- Diabetes	18 (24.0%)	16 (21.3%)
- Heart Disease	12 (16.0%)	9 (12.0%)
- Chronic Lung Disease	8 (10.7%)	7 (9.3%)
- Others	12 (16.0%)	11 (14.7%)

Biomarker Levels

Biomarker levels were evaluated in both the septic and nonseptic groups, and the results are presented in Table 2.

Table 2: Biomarker Levels in Septic and Non-Septic Groups

Biomarker	Septic Group (Mean ± SD)	Non-Septic Group (Mean ± SD)
C-reactive protein (CRP)	24.6 ± 10.4 mg/dL	5.2 ± 2.1 mg/dL
Procalcitonin (PCT)	3.8 ± 1.2 ng/mL	0.5 ± 0.3 ng/mL
Lactate	4.9 ± 1.8 mmol/L	2.1 ± 0.9 mmol/L
Interleukin-6 (IL-6)	115.3 ± 42.7 pg/mL	21.5 ± 8.3 pg/mL
Tumor necrosis factor-alpha (TNF-α)	64.8 ± 22.1 pg/mL	12.3 ± 5.5 pg/mL
Neutrophil-to-lymphocyte ratio (NLR)	11.6 ± 4.3	4.2 ± 1.6

Correlation between biomarkers and Sepsis

Statistical analysis revealed significant correlations between elevated biomarker levels and sepsis in ICU patients. The septic group exhibited significantly higher levels of CRP ($p < 0.001$), PCT ($p < 0.001$), lactate ($p < 0.001$), IL-6 ($p < 0.001$), TNF-α ($p < 0.001$), and NLR ($p < 0.001$) compared to the non-septic group (Table 3).

Table 3: Correlation between Biomarkers and Sepsis in ICU Patients

Biomarker	Correlation with Sepsis (p-value)
C-reactive protein (CRP)	$p < 0.001$
Procalcitonin (PCT)	$p < 0.001$
Lactate	$p < 0.001$
Interleukin-6 (IL-6)	$p < 0.001$
Tumor necrosis factor-alpha (TNF-α)	$p < 0.001$
Neutrophil-to-lymphocyte ratio (NLR)	$p < 0.001$

The p values indicate the statistical significance of the correlation between each biomarker and the presence of sepsis in ICU patients. A p-value less than 0.05 suggests a significant correlation.

Discussion

Sepsis is a severe medical condition that has a high risk of death, particularly for patients in the intensive care unit (ICU). Early detection and treatment of sepsis are vital for better patient outcomes. Biomarkers have gained significance in anticipating sepsis development and progression. Our research investigated various biomarkers to predict sepsis in ICU patients, highlighting the need for early diagnosis and proactive treatment.

Our analysis has shown that the ICU patient population is varied in terms of age and gender. It is crucial to conduct a comprehensive study that includes diverse demographics. The presence of comorbidities like hypertension and diabetes in these patients highlights the significance of understanding sepsis in relation to pre-existing health conditions.[4]

Our results show a significant correlation between the presence of sepsis in several biomarkers and a high level of some biomarkers in ICU patients. In septic patients, neutrophil to lymphocyte ratios (NLRs) were observed to be C-reactive proteins (CRPs), procalcitonin (PCTs), lactates, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-), and neutrophil to lymphocyte ratios (IL-6). These biomarkers indicate a systemic inflammation response characteristic of sepsis[5,6,7]

The presence of high levels of certain biomarkers has been found to be significantly linked to sepsis, indicating their potential for early detection of the condition in patients in the ICU. Two such biomarkers are CRP and PCT, which are known to be elevated in inflammatory conditions like sepsis. Lactate levels are also useful indicators of tissue hypoperfusion and organ dysfunction, which are common in sepsis. Furthermore, elevated levels of pro-inflammatory cytokines IL-6 and TNF-α provide further evidence of the inflammatory response associated with sepsis. Finally, the neutrophil-to-lymphocyte ratio (NLR) provides insight into the severity of systemic inflammation by reflecting the balance between immune response components[8,9]

Clinicians may use the relationship between biomarker levels and sepsis as a strategy for early detection and intervention. Early sepsis recognition can result in rapid administration of the right treatments, such as antibiotics and hemodynamic support, eventually improving patient outcomes. Combining these indicators might improve the precision and specificity of sepsis diagnosis[10,11]

But this study has several drawbacks. We are limited in our capacity to prove causation by the cross-sectional design. Additionally, because only one facility was included in the study, the results cannot be applied to other settings. Future investigations should concentrate on prospective, multicenter studies to confirm these results and improve the accuracy of biomarkers in predicting sepsis in patients in intensive care units.

Conclusion

In conclusion, this study emphasizes the potential for biomarkers including CRP, PCT, lactate, IL-6, TNF-, and NLR to foretell the onset and progression of sepsis in ICU patients. These biomarkers can operate as early warning systems, promoting proactive patient treatment and better clinical results. Biomarkers might alter the way sepsis is managed by allowing for early treatments and eventually saving lives by incorporating them into standard clinical practice.

References

1. Gyawali B, Ramakrishna K, Dhamoon AS. Sepsis: The evolution in definition, pathophysiology, and management. SAGE Open Med. 2019;7:2050312119835043. Published 2019 Mar 21.
2. Duncan CF, Youngstein T, Kirrane MD, Lonsdale DO. Diagnostic Challenges in Sepsis. Curr Infect Dis Rep. 2021;23(12):22.
3. Cho SY, Choi JH. Biomarkers of sepsis. Infect Chemother. 2014;46(1):1-12.
4. Brojakowska A, Eskandari A, Bisserier M, et al. Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients. PLoS One. 2021;16(7):e0253660. Published 2021 Jul 6.
5. Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci. 2013;50(1):23-36.
6. Vanimaya, Ravindran, S. et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. j intensive care. 2017; 5: 51.
7. Nargis W, Ibrahim M, Ahamed BU. Procalcitonin versus C-reactive protein: Usefulness as biomarker of sepsis in ICU patient. Int J Crit Illn Inj Sci. 2014;4(3):195-199.
8. Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view. Mediators Inflamm. 2013; 2013:165974.
9. Liu S, Wang X, She F, Zhang W, Liu H, Zhao X. Effects of Neutrophil-to-Lymphocyte Ratio Combined with Interleukin-6 in Predicting 28-Day Mortality in Patients with Sepsis. Front Immunol. 2021;12:639735. Published 2021 Mar 16.
10. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock

2021. Intensive Care Med. 2021;47(11):1181-1247.
11. Dolin HH, Papadimos TJ, Stepkowski S, Chen X, Pan ZK. A Novel Combination of Biomarkers to Herald the Onset of Sepsis Prior to the Manifestation of Symptoms. Shock. 2018;49(4):364-370.